arrow
R

Roman Kocián

Charles University
H指数:24
被引数:1,849

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Quality of life outcomes after sentinel lymph node biopsy in patients with early-stage cervical cancer: Results from the prospective multicentre SENTIX study

早期宫颈癌患者行前哨淋巴结活检术后的生活质量结局:来自前瞻性多中心SENTIX研究的结果

2026-08-100
PRE
Prospective comparison of diagnostic accuracy of ultrasound, PET/CT and DW-MRI for preoperative assessment of pelvic lymph nodes in cervical cancer patients: results of the CANNES trial

前瞻性比较超声、PET/CT和DW-MRI在宫颈癌患者术前评估盆腔淋巴结诊断准确性的研究:CANNES试验结果

2026-05-240
OA
Access to Molecular Classification in Endometrial Cancer recommended by ESGO-ESTRO-ESP guidelines: Multinational Survey in Eastern Europe

ESGO-ESTRO-ESP指南推荐的子宫内膜癌分子分型可及性:东欧跨国调查

2025-12-130
PRE
Sentinel lymph node mapping in early-stage cervical cancer: Results from the SENTIX prospective multicenter study

早期宫颈癌的哨兵淋巴结显像:SENTIX前瞻性多中心研究的结果

2025-10-090
PRE
Sentinel lymph node biopsy without systematic pelvic lymphadenectomy in females with early-stage cervical cancer: final outcome of the SENTIX prospective, single-arm, noninferiority, international trial

早期宫颈癌女性患者前哨淋巴结活检而不进行系统性盆腔淋巴结清扫术: SENTIX前瞻性单臂非劣效性国际试验的最终结果

2025-07-040
PRE
Sentinel Node Biopsy Using Two Concurrent Labeling Techniques (Radioactive Tracer With/Without Blue Dye vs. Indocyanin Green-ICG) in Early-Stage Endometrial Cancer Patients (TESLA-1): A Prospective Observational Study CEEGOG EX-02

早期子宫内膜癌患者应用两种并行标记技术的哨兵淋巴结活检(放射性示踪剂联合/不联合蓝染料与吲哚菁绿-ICG)(TESLA-1):一项前瞻性观察研究 CEEGOG EX-02

CANCERS
IF4.4
2025-05-090
OA
Preoperative tumour size assessment in patients with early-stage cervical cancer: Final results of the SENTIX study

早期宫颈癌患者术前肿瘤大小评估:SENTIX研究的最终结果

2025-05-010
PRE
ISUOG/ESGO Consensus Statement on ultrasound-guided biopsy in gynecological oncology

ISUOG/ESGO关于妇科肿瘤学中超声引导下活检的共识声明

2025-04-010
OAAI
Ability Of Imaging Methods To Predict Surgical Outcome In Patients With Tubo-Ovarian Carcinoma Using ESMO-ESGO Criteria: A Prospective ISAAC Study

利用ESMO-ESGO标准评估影像学方法预测输卵管卵巢癌患者手术疗效的能力:一项前瞻性ISAAC研究

2025-02-010
PRE
Final overall survival (OS) from the phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR)

III期ATALANTE/ENGOT-ov29试验最终总生存期(OS)结果,该试验评估了在铂敏感复发的卵巢癌(OC)患者(pts)中,阿替利珠单抗(Atz)与安慰剂联合标准化疗(Cx)加贝伐珠单抗(bev)的比较。

2024-09-011
PRE
Tertiary prevention strategies for micrometastatic lymph node cervical cancer: A systematic review and a prototype of an adapted model of care
2024-05-011
PRE
Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer

三级淋巴结构和b细胞决定卵巢癌的临床相关T细胞表型

2024-03-2113
OAAI
Patient satisfaction with ultrasound, CT and WB-DWI/MRI for preoperative ovarian cancer staging: a multicentre prospective survey
2023-10-021
OAAI
Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study
2022-01-0140
OAAI